Royalty Pharma plc (RPRX): debt financing — Royalty Pharma draws $350M from revolver to fund Evrysdi royalty purchase

Royalty Pharma plc

Subsidiary borrowed $350M under $1.5B five-year unsecured revolver on Oct 18, 2023.
Proceeds to partially fund previously announced purchase of additional Evrysdi royalties from PTC Therapeutics.
Revolving credit facility originally dated Sept 15, 2021; amended Oct 31, 2022 (exhibit 10.1).
Borrowing is within existing $1.5B capacity; no other material terms changed.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.95

Royalty Pharma plc incurred revolving credit of $350 million with Royalty Pharma Holdings Ltd at not specified maturing five-year unsecured revolving credit facility.

Instrument: revolving credit
Principal: $350 million
Counterparty: Royalty Pharma Holdings Ltd
Rate: not specified
Maturity: five-year unsecured revolving credit facility
Event: incurrence

Exact text from the filing

Royalty Pharma Holdings Ltd, a subsidiary of Royalty Pharma plc, borrowed $350 million under its existing five-year unsecured revolving credit facility (the "Revolving Credit Facility") to fund a portion of its previously announced purchase of additional royalties on Roche's Evrysdi ® (risdiplam) from PTC Therapeutics, Inc.

View on SEC.gov

Browse all debt financings →

Royalty Pharma plc filing history →

Source: SEC EDGAR

accession 0001193125-23-258997

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.